Braveheart Bio, Inc. reported unaudited financial results for the quarter ended June 30, 2026, reporting a net loss of $15.0 million ($2.51 per share) and cash and cash equivalents of $122.8 million. The company initiated its Phase 3 LIONHEART-HCM trial for BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM), with first patient dosing expected later this year, while planning to start the NOBLEHEART-HCM Phase 3 trial for non-obstructive HCM (nHCM) in early 2027. Braveheart Bio completed an initial public offering in August 2026, raising approximately $404.5 million in net proceeds, bringing total cash resources to roughly $527.3 million on an as-adjusted basis and extending its funding runway into 2029. The company is a clinical-stage biopharmaceutical firm developing therapies for hypertrophic cardiomyopathy.

Braveheart Bio, Inc. filed its second amended and restated certificate of incorporation with the Delaware Secretary of State on August 7, 2026, in connection with the completion of its initial public offering. The charter amendments authorize 500,000,000 shares of common stock, eliminate references to previously existing preferred stock series, and authorize 10,000,000 shares of undesignated preferred stock issuable at the Board's discretion. Additionally, the filing eliminates shareholder ability to take action by written consent or call special meetings. The company also adopted second amended and restated bylaws establishing formal meeting procedures and advance notice requirements for stockholder proposals. Braveheart Bio, Inc. operates in the biotechnology industry, focusing on drug discovery and development.